US20230181487A1 - Compositions in support of health and mental accuity - Google Patents
Compositions in support of health and mental accuity Download PDFInfo
- Publication number
- US20230181487A1 US20230181487A1 US18/107,348 US202318107348A US2023181487A1 US 20230181487 A1 US20230181487 A1 US 20230181487A1 US 202318107348 A US202318107348 A US 202318107348A US 2023181487 A1 US2023181487 A1 US 2023181487A1
- Authority
- US
- United States
- Prior art keywords
- range
- composition
- extract
- present
- awake
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 279
- 230000003340 mental effect Effects 0.000 title description 12
- 230000036541 health Effects 0.000 title description 3
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 48
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000284 extract Substances 0.000 claims abstract description 44
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 30
- 239000009405 Ashwagandha Substances 0.000 claims abstract description 26
- 235000001978 Withania somnifera Nutrition 0.000 claims abstract description 26
- 240000004482 Withania somnifera Species 0.000 claims abstract description 26
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 claims abstract description 26
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004615 ingredient Substances 0.000 claims abstract description 21
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001948 caffeine Drugs 0.000 claims abstract description 18
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 17
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 13
- 241000196324 Embryophyta Species 0.000 claims abstract description 12
- 241000190633 Cordyceps Species 0.000 claims abstract description 8
- 238000013265 extended release Methods 0.000 claims abstract description 8
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 7
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 7
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 7
- 235000015191 beet juice Nutrition 0.000 claims abstract description 6
- 241000533293 Sesbania emerus Species 0.000 claims description 7
- 240000007124 Brassica oleracea Species 0.000 claims description 5
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 5
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 5
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 5
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 5
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 5
- 235000005805 Prunus cerasus Nutrition 0.000 claims description 5
- 240000002878 Prunus cerasus Species 0.000 claims description 5
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 5
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 5
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 5
- 229940069765 bean extract Drugs 0.000 claims description 5
- 235000021014 blueberries Nutrition 0.000 claims description 5
- 235000020688 green tea extract Nutrition 0.000 claims description 5
- 229940094952 green tea extract Drugs 0.000 claims description 5
- 239000008513 turmeric extract Substances 0.000 claims description 5
- 235000020240 turmeric extract Nutrition 0.000 claims description 5
- 229940052016 turmeric extract Drugs 0.000 claims description 5
- PQZVBIJEPVKNOZ-PCLZMVHQSA-N (2R)-2-[(1S)-1-hydroxy-1-[(5R,6R,8R,9S,10R,13S,14R,17S)-5,6,14,17-tetrahydroxy-10,13-dimethyl-1-oxo-6,7,8,9,11,12,15,16-octahydro-4H-cyclopenta[a]phenanthren-17-yl]ethyl]-4,5-dimethyl-2,3-dihydropyran-6-one Chemical class C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@]1(O)[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=CC[C@]4(O)[C@H](O)C[C@H]3[C@]2(O)CC1 PQZVBIJEPVKNOZ-PCLZMVHQSA-N 0.000 claims description 3
- JAVFSUSPBIUPLW-QEWGJZFKSA-N Withanolide Natural products O=C1[C@@H](C)[C@H](C)C[C@H]([C@@H](C)[C@@H]2[C@@]3(C)[C@H]([C@@H]4[C@@H]([C@]5(C)[C@@H](CC4)CCCC5)CC3)CC2)O1 JAVFSUSPBIUPLW-QEWGJZFKSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 description 56
- 229930003827 cannabinoid Natural products 0.000 description 31
- 239000003557 cannabinoid Substances 0.000 description 31
- 150000003505 terpenes Chemical class 0.000 description 29
- 235000007586 terpenes Nutrition 0.000 description 29
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 25
- 239000000843 powder Substances 0.000 description 17
- 240000002999 Bacopa monnieri Species 0.000 description 16
- 235000015418 Bacopa monnieria Nutrition 0.000 description 16
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 16
- 244000025254 Cannabis sativa Species 0.000 description 16
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 16
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 16
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 16
- 235000009120 camo Nutrition 0.000 description 16
- 235000005607 chanvre indien Nutrition 0.000 description 16
- 239000011487 hemp Substances 0.000 description 16
- 240000004371 Panax ginseng Species 0.000 description 15
- 235000008434 ginseng Nutrition 0.000 description 15
- 159000000003 magnesium salts Chemical class 0.000 description 15
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 14
- 230000008901 benefit Effects 0.000 description 14
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 14
- -1 50 mg to 350 mg Chemical compound 0.000 description 13
- 235000003713 Rhodiola rosea Nutrition 0.000 description 13
- 244000042430 Rhodiola rosea Species 0.000 description 13
- 229960003453 cannabinol Drugs 0.000 description 13
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 12
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 12
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 12
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 12
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 12
- 229950011318 cannabidiol Drugs 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 12
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 12
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 12
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 12
- 229960003987 melatonin Drugs 0.000 description 12
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 12
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 12
- 235000016068 Berberis vulgaris Nutrition 0.000 description 11
- 241000335053 Beta vulgaris Species 0.000 description 11
- 241000045403 Astragalus propinquus Species 0.000 description 10
- 241001289529 Fallopia multiflora Species 0.000 description 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 10
- 240000008397 Ganoderma lucidum Species 0.000 description 10
- 244000194101 Ginkgo biloba Species 0.000 description 10
- 241000756042 Polygonatum Species 0.000 description 10
- 244000126002 Ziziphus vulgaris Species 0.000 description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 9
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 8
- 235000013793 astaxanthin Nutrition 0.000 description 8
- 239000001168 astaxanthin Substances 0.000 description 8
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 8
- 229940022405 astaxanthin Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 7
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 7
- 235000013832 Valeriana officinalis Nutrition 0.000 description 7
- 244000126014 Valeriana officinalis Species 0.000 description 7
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 7
- 229930006739 camphene Natural products 0.000 description 7
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 7
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 7
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 7
- 235000016788 valerian Nutrition 0.000 description 7
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 7
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 7
- 235000008209 xanthohumol Nutrition 0.000 description 7
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 description 6
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 6
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 6
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 235000015489 Emblica officinalis Nutrition 0.000 description 6
- 235000015459 Lycium barbarum Nutrition 0.000 description 6
- 244000241838 Lycium barbarum Species 0.000 description 6
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 description 6
- 235000002789 Panax ginseng Nutrition 0.000 description 6
- 240000009120 Phyllanthus emblica Species 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 6
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 6
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 235000001510 limonene Nutrition 0.000 description 6
- 229940087305 limonene Drugs 0.000 description 6
- 229930007744 linalool Natural products 0.000 description 6
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 description 6
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 5
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 241000132012 Atractylodes Species 0.000 description 5
- 241000092665 Atractylodes macrocephala Species 0.000 description 5
- 241001474374 Blennius Species 0.000 description 5
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 5
- 235000008100 Ginkgo biloba Nutrition 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 235000004072 Ocimum sanctum Nutrition 0.000 description 5
- 240000002837 Ocimum tenuiflorum Species 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 5
- 235000004506 Polygonatum multiflorum Nutrition 0.000 description 5
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 5
- 241000264279 Sargassum fusiforme Species 0.000 description 5
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 5
- 235000006533 astragalus Nutrition 0.000 description 5
- 229930006722 beta-pinene Natural products 0.000 description 5
- 229960005233 cineole Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 5
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 5
- 244000237330 gutta percha tree Species 0.000 description 5
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 150000007823 ocimene derivatives Chemical class 0.000 description 5
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 5
- GDVRUDXLQBVIKP-HQHREHCSSA-N 1-O-galloyl-beta-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-HQHREHCSSA-N 0.000 description 4
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001409321 Siraitia grosvenorii Species 0.000 description 4
- IGHTZQUIFGUJTG-UHFFFAOYSA-N cannabicyclol Chemical compound O1C2=CC(CCCCC)=CC(O)=C2C2C(C)(C)C3C2C1(C)CC3 IGHTZQUIFGUJTG-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 241001632410 Eleutherococcus senticosus Species 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 244000185386 Thladiantha grosvenorii Species 0.000 description 3
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229920002770 condensed tannin Polymers 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940004916 magnesium glycinate Drugs 0.000 description 3
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 description 3
- 229940082473 melissa officinalis leaf extract Drugs 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 2
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 2
- IXJXRDCCQRZSDV-GCKMJXCFSA-N (6ar,9r,10as)-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6h-1,9-epoxybenzo[c]chromene Chemical compound C1C[C@@H](C(O2)(C)C)[C@@H]3C[C@]1(C)OC1=C3C2=CC(CCCCC)=C1 IXJXRDCCQRZSDV-GCKMJXCFSA-N 0.000 description 2
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 2
- 241000220433 Albizia Species 0.000 description 2
- 235000011468 Albizia julibrissin Nutrition 0.000 description 2
- 240000007185 Albizia julibrissin Species 0.000 description 2
- 235000011438 Albizia odoratissima Nutrition 0.000 description 2
- 241000510654 Bupleurum chinense Species 0.000 description 2
- 241000202722 Bupleurum falcatum Species 0.000 description 2
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 2
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 2
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 2
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 2
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 2
- 241001284615 Frangula californica Species 0.000 description 2
- 229920000296 Glucogallin Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001080798 Polygala tenuifolia Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 229930190519 bacopaside Natural products 0.000 description 2
- GDVRUDXLQBVIKP-UHFFFAOYSA-N beta-D-glucogallin Natural products OC1C(O)C(O)C(CO)OC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 2
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 2
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940074358 magnesium ascorbate Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229960005336 magnesium citrate Drugs 0.000 description 2
- 239000004337 magnesium citrate Substances 0.000 description 2
- 235000002538 magnesium citrate Nutrition 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- AIOKQVJVNPDJKA-ZZMNMWMASA-L magnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] AIOKQVJVNPDJKA-ZZMNMWMASA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OGLDWXZKYODSOB-UHFFFAOYSA-N α-phellandrene Chemical compound CC(C)C1CC=C(C)C=C1 OGLDWXZKYODSOB-UHFFFAOYSA-N 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 description 1
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 1
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- PSVBPLKYDMHILE-UHFFFAOYSA-N alpha-humulene Natural products CC1=C/CC(C)(C)C=CCC=CCC1 PSVBPLKYDMHILE-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- OGLDWXZKYODSOB-SNVBAGLBSA-N alpha-phellandrene Natural products CC(C)[C@H]1CC=C(C)C=C1 OGLDWXZKYODSOB-SNVBAGLBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- This disclosure in general, is directed to ingestible compositions in support of health and mental acuity and associated methods.
- compositions that address or improve the quality of sleep or compositions that support productivity without introducing additional stress would be desirable.
- FIG. 1 includes a block flow diagram of an example method of using a composition.
- FIG. 2 includes a block flow diagram of an example method of making a composition.
- a composition in an embodiment, includes ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, and amla in a range of 0.5% to 10%.
- the composition can further include one or more cannabinoid agents, such as cannabidiol (CBD), cannabinol (CBN) or cannabigerol (CBG).
- CBD cannabidiol
- CBN cannabinol
- CBG cannabigerol
- the composition provides benefits in both formulas for improved mental acuity, referred to herein as an alert formula or composition, and formulas for improved sleep, referred to herein as a sleep formula or composition.
- the composition includes a cannabinoid agent, such as cannabinol (CBN) or cannabigerol (CBG).
- the composition further includes a co-fermented herbal complex in which a set of herbs are fermented together in the same solution.
- the composition includes a variety of terpenes.
- the composition includes ashwagandha.
- the composition may be in the form of a powder.
- the power can be mixed with water to form an aqueous solution that is imbibed by a user.
- Such compositions have use to improve both awake time mental acuity and quality of sleep.
- percentages are expressed as a weight percent, and weights are expressed on a per dose basis. For example, if a recommended dose of the dry powder composition is 10 grams, the weights of the ingredients of the composition are expressed as weights of the ingredient within 10 grams of the dry powder composition.
- the compositions can be mixed with water or other liquids and the weights or weight percentages are expressed to not include the water or other liquid because more or less liquid can be used to concentrate or dilute a liquid version of the composition or formula, if any.
- per-dose refers to the recommended dose provided with a product including the composition or formula and includes any dose option within the full range of dose options provided with the product. For example, if the product recommends one to two scoops as a dose, the per-dose composition includes the composition of one scoop or the composition of two scoops.
- a composition includes ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, and amla in a range of 0.5% to 10%.
- the composition provides benefits in both formulas for improved mental acuity, referred to herein as an alert formula or composition, and formulas for improved sleep, referred to herein as a sleep formula or composition.
- the composition can include the ashwagandha in a range of 7% to 15%.
- the composition can include the ashwagandha in a range of 9% to 13%.
- the ashwagandha can include withanolides.
- the composition can include withanolides in a per dose basis in a range of 5 mg to 30 mg, such as 10 mg to 20 mg.
- the composition can include the bacopa monnieri in a range of 4% to 10%.
- the bacopa monnieri in a range of 4% to 7%.
- the bacopa monnieri includes bacopasides.
- the bacopasides can be included in a per dose basis in a range of 50 mg to 300 mg, such as 100 mg to 200 mg.
- the composition can include the amla (embllica officinals) in a range of 1.5% to 5%.
- the amla can include beta-glucogallin.
- the composition can include the beta-glucogallin on a per dose bases in a range of 1 mg to 30 mg, such as a range of 3 mg to 10 mg.
- the composition can include a cannabinoid agent.
- the composition can include cannabidiol (CBD) in a range of 1% to 10%.
- the cannabidiol can be included in a range of 3% to 7%.
- the composition includes cannabinol (CBN) in a range of 0.1% to 4%.
- the cannabinol can be present in a range of 1% to 3%.
- composition finds particular use in either a formula or composition that enhances mental acuity (referred to herein as an alert formula or composition) or a formula or composition that improves sleep (referred to herein as a sleep formula or composition).
- an alert composition includes plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%.
- the composition includes the plant-based nitric oxide-inducing ingredients are present in a range of 0.5% to 5%, such as in a range of 0.5% to 3%.
- the plant-based nitric oxide inducing ingredients can include one or more of green coffee bean extract, green tea extract, tart cherry, blueberry, broccoli, kale, or turmeric extract.
- the pant-based nitric oxide inducing ingredients is S7TM of FutureCeuticals.
- the alert composition includes coffee fruit extract in a range of 0.5% to 10%.
- the coffee fruit extract is present in a range of 0.5% to 5%.
- the coffee fruit extract is present in a range of 0.5% to 3%.
- the alert composition includes grape seed extract in a range of 1% to 10%.
- the grape seed extract is present in a range of 1% to 5%.
- the grape seed extract can include proanthocyanidins.
- the alert composition can include 25 mg to 200 mg of the proanthocyanidins, such as 50 mg to 120 mg of the proanthocyanidins.
- the alert composition includes Cordyceps ( Cordyceps sinensis ) in a range of 5% to 20%.
- the alert composition can include the Cordyceps in a range of 7% to 15%, such as a range of 9% to 13%.
- the Cordyceps can include cordycepic acid.
- the alert composition can include the cordycepic acid in an amount in a range of 5 mg to 50 mg, such as a range of 10 mg to 30 mg.
- the alert composition includes extended-release caffeine in a range of 0.5% to 10%.
- the extended-release caffeine can be included in a range of 0.5% to 5%, such as a range of 0.5% to 3%.
- the various coffee products and extracts and the extended-release caffeine provide caffeine to the alert composition.
- the alert composition can include 50 mg to 500 mg caffeine, such as 50 mg to 350 mg, or 100 mg to 250 mg caffeine on a per dose basis, in both or either quick release or extended-release variations.
- the alert composition includes whole coffee fruit extract in a range of 1% to 10%.
- the whole coffee fruit extract is present in a range of 1% to 5%.
- the alert composition includes Schisandra extract in a range of 1% to 10%.
- the Schisandra extract is present in a range of 4% to 10%, such as in a range of 4% to 7%.
- the alert composition includes L-theanine in a range of 1% to 10%.
- the L-theanine is present in a range of 4% to 10%, such as in a range of 4% to 7%.
- the alert composition includes beet juice in dried form in a range of 20% to 60%.
- the beet juice is present in a range of 30% to 50%.
- the alert composition can further include dextrin and various flavorings.
- the composition can be used along with other ingredients to form a sleep composition.
- the sleep composition can include melatonin in a range of 0.005% to 1%.
- the melatonin can be included in a range of 0.01% to 0.5%, such as in a range of 0.01% to 0.1%.
- the sleep composition can include Bluenesse ( Melissa officinalis leaf extract) in a range of 3% to 20%.
- Bluenesse Melissa officinalis leaf extract
- the Melissa officinalis leaf extract is present in a range of 5% to 18%, such as in a range of 10% to 15%.
- the sleep composition can include holy basil ( ocimum tenuiflorum ) in a range of 20% to 60%.
- the holy basil is present in a range of 30% to 50%.
- the sleep composition can include gamma aminobutyric acid in a range of 0.5% to 10%.
- the gamma aminobutyric acid is present in a range of 1.5% to 5%.
- the sleep composition includes L-theanine in a range of 1% to 10%.
- the L-theanine is present in a range of 4% to 10%, such as in a range of 6% to 9%.
- an alert composition consists essentially of ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, amla in a range of 0.5% to 10%, cannabidiol in a range of 1% to 10%, cannabinol in a range of 0.1% to 4%, plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%, coffee fruit extract in a range of 0.5% to 10%, grape seed extract in a range of 1% to 10%, Cordyceps in a range of 5% to 20%, extended-release caffeine in a range of 0.5% to 10%, whole coffee fruit extract in a range of 1% to 10%, Schisandra extract in a range of 1% to 10%, L-theanine in a range of 1% to 10%, beet juice in a range of 20% to 60%, and dextrin.
- the plant-based nitric oxide inducing ingredients include one or more of green coffee bean extract, green tea extract, tart cherry, blueberry, broccoli, kale, or turmeric extract.
- a sleep composition consists essentially of ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, amla in a range of 0.5% to 10%, cannabidiol in a range of 1% to 10%, cannabinol in a range of 0.1% to 4%, melatonin in a range of 0.005% to 1%, Melissa officinalis leaf extract in a range of 3% to 20%, holy basil ( ocimum tenuiflorum ) in a range of 20% to 60%, and gamma aminobutyric acid in a range of 0.5% to 10%.
- the sleep composition can further include sweeteners and flavorings.
- an alternative alert composition consists essentially of complex terpenes in a range of 0.5% to 10%, coffee fruit extract in a range of 5% to 20%, organic coffeeberry in a range of 5% to 20%, plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%, cannabidiol in a range of 0.1% to 5%, cannabinol in a range of 0.1% to 3%, epigallocatechin gallate in a range of 0.005% to 1%, and resveratrol in a range of 0.005% to 1%.
- the composition can further include sweeteners, such as dextrin and monk fruit extract, and flavorings, such as citric acid.
- the complex terpenes are present in a range of 0.5% to 5%, such as in a range of 0.5% to 3%.
- the complex terpenes can include alpha pinene, limonene, beta caryophyllene, phytol, alpha phellandrene, alpha-humulene, nerolidol, myrcene, linalool, terpinolene, or any combination thereof.
- the coffee fruit extract is present in a range of 10% to 15%.
- the organic coffeeberry is present in a range of 10% to 15%.
- the plant-based nitric oxide-inducing ingredients in a range of 1% to 10%, such as in a range of 2% to 8%.
- the cannabidiol is present in a range of 0.5% to 3%. In an additional example, the cannabinol is present in a range of 0.5% to 2%.
- the epigallocatechin gallate is present in a range of 0.01% to 0.5%.
- the epigallocatechin gallate is present in a range of 0.01% to 0.1%.
- the resveratrol is present in a range of 0.01% to 0.5%.
- the resveratrol is present in a range of 0.01% to 0.1%.
- the composition includes a cannabinoid agent, a terpene agent, and co-fermented herbal complex.
- the composition may be a dry powdered mixture.
- the composition can be in the form of an aqueous solution.
- the cannabinoid agent can include CBD (cannabidiol), CBDA (cannabidiolic acid), CBN (cannabinol), CBG (cannabigerol), CBC (cannabichromene), CBL (cannabicyclol), CBV (cannabivarin), THCV (tetrahydrocannabivarin), CBDV (cannabidivarin), CBCV (cannabichromevarin), CBGV (cannabigerovarin), CBGM (cannabigerol monomethyl ether), CBE (cannabielsoin), CBT (cannabicitran), or any combination thereof.
- the cannabinoid agent is free of THC (tetrahydrocannabinol) or THCA (tetrahydrocannabinolic acid).
- the cannabinoid includes CBD, CBN, CBG, or combination thereof.
- the cannabinoid agent includes CBG.
- the cannabinoid agent includes CBN.
- the cannabinoid agent can be included in the composition in a range of 0.005% to 1%.
- the cannabinoid agent can be included in the composition in a range of 0.01% to 1%, such as a range of 0.01% to 0.5%.
- the terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof.
- the terpene agent includes a mixture including limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, or a combination thereof.
- the terpene agent includes camphene, mycene, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof.
- the terpene agent can be included in the composition in a range of 0.005% to 1%.
- the terpene agent can be included in the composition in a range of 0.1% to 0.5%.
- each of the ingredients can be fermented together and subsequently dried to form a powder complex having synergistic properties.
- the co-fermented herbal complex can include ginseng , maidenhair tree ( Ginkgo biloba ), Mongolian milkvetch ( Astragalus membranaceus ), magnolia vine ( Schisandra chinensis ), fo-ti ( polygonum multiflorum ), hardy rubber Tree ( Eucommiae ulmoides ), Solomon's seal ( polygonatum sibirica ), hijiki seaweed (sargassum fusiforme ), white atractylodes ( Atractylodes macrocephala ), reishi mushroom ( Ganoderma lucidum ), or any combination thereof.
- the ginseng of the co-fermented herbal complex can include Siberian ginseng (eletherococcus senticosus ), Chinese ginseng ( panax ginseng ), southern ginseng ( Gynostemma pentaphylla ), or any combination thereof.
- the co-fermented herbal complex can further include jujube fruit ( Ziziphus jujuba ), Goji berry ( lycium barbarum), monk fruit ( momordica grosvenori ), or any combination thereof.
- the for co-fermented herbal complex includes Siberian ginseng (eletherococcus senticosus ), maidenhair tree ( Ginkgo biloba ), Mongolian milkvetch ( Astragalus membranaceus ), Chinese ginseng ( panax ginseng ), magnolia vine ( Schisandra chinensis ), fo-ti ( Polygonum multiflorum ), hardy rubber Tree ( Eucommiae ulmoides ), Solomon's seal ( polygonatum sibirica ), southern ginseng ( Gynostemma pentaphylla ), hijiki seaweed (sargassum fusiforme ), white atractylodes ( Atractylodes macrocephala ), reishi mushroom ( Ganoderma lucidum ), jujube fruit ( Ziziphus jujuba ), Goji berry ( Lycium barbarum ), monk fruit ( momordica grosvenori ), or any combination thereof.
- the co-fermented herbal complex includes Chinese jujube seed ( Ziziphus jujuba ), Chinese thoroughwax ( Bupleurum falcatum ), Chinese senega root (poygala tenuifolia ), albizia bark ( Albizzia julibrissin ), sphora root ( Sophora flavescens ), or any combination thereof.
- the co-fermented herbal complex can be included in the composition in a range of 5% to 40%.
- the co-fermented herbal complex is included in the composition in a range of 10% to 30%, such as a range of 15% to 35%.
- the composition can further include fermented beet.
- the fermented beet can be fermented beet crystals.
- the fermented beet can be included in the composition in the range of 1% to 30%, such as a range of 5% to 20%.
- the composition can include Rhodiola rosea .
- the Rhodiola rosea can be a fermented Rhodiola rosea .
- the Rhodiola rosea is included in the composition in a range of 1% to 10%, such as a range of 2% to 7%.
- the composition can further include Cordyceps sinensis .
- the Cordyceps sinensis can include fermented Cordyceps sinensis .
- the Cordyceps sinensis is included in the composition in a range of 1% to 10%, such as a range of 2% to 7%.
- the composition can include hemp extract, such as THC-free hemp extract.
- the hemp extract can be included in the composition in a range of 0.01% to 2%, such as a range of 0.05% to 1%.
- the composition can include bacopa monnieri.
- the bacopa monnieri can be included in the composition in a range of 1% to 10%.
- the bacopa monnieri can be included in a range of 2% to 7%.
- the composition can also include L-theanine, such as fermented L-theanine.
- L-theanine such as fermented L-theanine.
- the L-theanine is included in the composition in a range of 1% to 10%, such as a range of 1% to 6%.
- the composition can include whole bean coffee fruit powder.
- the whole bean coffee fruit powder can be included in the composition in a range of 0.1% to 5%.
- the whole bean coffee fruit powder can be included in the composition in a range of 0.5% to 3%.
- the composition can also include caffeine, such as an organic derived caffeine.
- the caffeine can be included in the composition in a range of 0.5% to 10%, such as a range of 1% to 5%.
- the composition can also include a nitric oxide booster.
- the nitric oxide booster includes coffee bean extract, green tea extract, turmeric extract, tart cherry, blueberry, broccoli, kale, or any combination thereof.
- the nitric oxide booster can be included in the composition in a range of 0.01% to 5%, such as a range of 0.1% to 2%.
- the composition can include astaxanthin.
- the composition can include astaxanthin in a range of 0.01% to 2%, such as a range of 0.01% to 1%.
- the composition can include xanthohumol.
- the composition can include the xanthohumol in a range of 0.01% to 2%, such as a range of 0.01% to 1%.
- the composition can include a source of magnesium, such as magnesium oxide or magnesium salt.
- the magnesium salt can include magnesium chloride, magnesium nitrate, or an organic magnesium salt.
- the magnesium salt can be an organic magnesium salt, such as magnesium citrate, magnesium glycinate, magnesium ascorbate, or any combination thereof.
- the magnesium salt can be included in the composition in the range of 1% to 15%, such as a range of 2% to 10%.
- the composition can include ashwagandha, such as an organic ashwagandha.
- ashwagandha can be included in the composition in a range of 1% to 15%, such as a range of 2% to 10%.
- the composition can include valerian root.
- the valerian root can be included in the composition in a range of 0.1% to 2%, such as a range of 0.1% to 1%.
- the composition can include melatonin.
- the melatonin can be included in a composition in a range of 0.005% to 0.5%, such as a range of 0.01% to 0.1%.
- the composition can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar or stevia ; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof.
- the composition can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof.
- the filler includes maltodextrin.
- the composition can include a dispersant, such as lecithin.
- the composition can be in a powder form.
- the composition can be in the form of pressed tablets or in the form of capsules.
- the composition can be mixed with water to form an aqueous solution.
- an awake composition can promote mental acuity during periods when users are awake.
- the composition can include a cannabinoid agent, such as CBG, a terpene agent, and a co-fermented herbal complex.
- the awake composition can include Rhodiola rosea, Cordyceps sinensis , or astaxanthin, or any combination thereof.
- the awake composition includes the cannabinoid agent in a range of 0.05% to 1%.
- the cannabinoid agent can be included in the awake composition in a range of 0.01% to 1%, such as a range of 0.1% to 0.5%.
- the cannabinoid agent can be included in the awake composition in a range of 0.5 mg to 5 mg.
- the cannabinoid agent can be included in the awake composition in a range of 0.5 mg to 3 mg, such as a range of 1 mg to 2.5 mg.
- the terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof.
- the terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, or a combination thereof.
- the terpene agent is included in the awake composition in a range of 0.05% to 1%.
- the terpene agent can be included in the awake composition in a range of 0.005% to 1%, such as a range of 0.1% to 0.5%.
- the terpene agent can be included in the awake composition in a range of 1 mg to 10 mg.
- the terpene agent can be included in the awake composition in a range of 2 mg to 7 mg.
- the co-fermented herbal complex can include ginseng , maidenhair tree ( Ginkgo biloba ), Mongolian milkvetch ( Astragalus membranaceus ), magnolia vine ( Schisandra chinensis ), fo-ti ( Polygonum multiflorum ), hardy rubber Tree ( eucommiae ulmoides ), Solomon's seal ( polygonatum sibirica ), hijiki seaweed (sargassum fusiforme ), white Atractylodes ( Atractylodes macrocephala ), reishi mushroom ( Ganoderma lucidum ), or any combination thereof.
- the ginseng of the co-fermented herbal complex can include Siberian ginseng (eletherococcus senticosus ), Chinese ginseng ( panax ginseng ), southern ginseng ( Gynostemma pentaphylla ), or any combination thereof.
- the co-fermented herbal complex can further include jujube fruit ( Ziziphus jujuba ), Goji berry ( Lycium barbarum ), monk fruit ( Momordica grosvenori ), or any combination thereof.
- the co-fermented herbal complex can be included in the awake composition in a range of 5% to 40%.
- the co-fermented herbal complex can be included in the awake composition in a range of 10% to 30%, such as a range of 15% to 25%.
- the co-fermented herbal complex can be included in the awake composition in a range of 1500 mg to 3000 mg.
- the co-fermented herbal complex can be included in the awake composition in a range of 1500 mg to 2500 mg, such as a range of 1750 mg to 2250 mg.
- the Rhodiola rosea can be a fermented Rhodiola rosea .
- the Rhodiola rosea can be included in the awake composition in a range of 1% to 10%.
- the Rhodiola rosea can be included in the awake composition in a range of 2% to 7%.
- the Rhodiola rosea can be included in the awake composition in a range of 200 mg to 500 mg.
- the Rhodiola rosea can be included in the awake composition in a range of 300 mg to 400 mg.
- the Cordyceps sinensis can be fermented Cordyceps sinensis .
- the Cordyceps sinensis can be included in the awake composition in a range of 1% to 10%.
- the Cordyceps sinensis can be included in the awake composition in a range of 2% to 7%.
- the Cordyceps sinensis can be included in the awake composition in a range of 200 mg to 500 mg.
- the Cordyceps sinensis can be included in the awake composition in a range of 300 mg to 400 mg.
- the astaxanthin can be included in the awake composition in a range of 0.01% to 2%.
- the astaxanthin can be included in the awake composition in a range of 0.01% to 1%.
- the astaxanthin can be included in the awake composition in a range of 1 mg to 20 mg, such as a range of 2 mg to 15 mg.
- the composition can further include fermented beet, such as fermented beet crystals.
- the fermented beet can be included in the awake composition in a range of 1% to 30%, such as a range of 5% to 20%.
- the fermented beet can be included in the awake composition in a range of 600 mg to 1800 mg.
- the fermented beet can be included in the awake composition in a range of 1000 mg to 1400 mg.
- the composition can further include hemp extract, such as THC-free hemp extract.
- hemp extract such as THC-free hemp extract.
- the hemp extract is included in the awake composition in a range of 0.01% to 2%, such as a range of 0.05% to 1%.
- the hemp extract can be included in the awake composition in a range of 5 mg to 35 mg, such as a range of 10 mg to 25 mg.
- the awake composition can further include bacopa monnieri.
- the bacopa monnieri can be included in the awake composition in a range of 1% to 10%, such as a range of 2% to 7%.
- the bacopa monnieri can be included in the awake composition in a range of 150 mg to 500 mg.
- the bacopa monnieri can be included in the awake composition in a range of 200 mg to 400 mg.
- the awake composition can also include L-theanine, such as a fermented L-theanine.
- L-theanine is included in the awake composition in a range of 1% to 10%, such as a range of 1% to 6%.
- the L-theanine can be included in the awake composition in a range of 100 mg to 400 mg, such as a range of 150 mg to 300 mg.
- the awake composition can also include whole coffee being fruit powder.
- the whole coffee bean fruit powder can be included in the awake composition in a range of 0.1% to 5%, such as a range of 0.5% to 3%.
- the whole coffee bean fruit powder can be included in the awake composition in a range of 10 mg to 300 mg, such as a range of 50 mg to 250 mg.
- the awake composition can also include caffeine.
- the caffeine can be included in the awake composition in a range of 0.5% to 10%, such as a range of 1% to 5%.
- the caffeine is included in the awake composition in a range of 20 mg to 500 mg, such as a range of 100 mg to 400 mg.
- the awake composition can further include a nitric oxide booster.
- the nitric oxide booster includes coffee bean extract, green tea extract, turmeric extract, tart cherry, blueberry, broccoli, kale, or any combination thereof.
- the nitric oxide booster can be included in the awake composition in a range of 0.1% to 5%, such as a range of 0.1% to 2%.
- the nitric oxide booster can be included in the awake composition in a range of 10 mg to 150 mg.
- the nitric oxide booster can be included in the awake composition in a range of 25 mg to 90 mg.
- the awake composition can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar, sugar alcohols, or stevia ; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof.
- the composition can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof.
- the composition can include a dispersant, such as lecithin.
- the awake composition can be in a powder form.
- the awake composition can be in the form of pressed tablets or in the form of capsules.
- the awake composition can be mixed with water to form an aqueous solution.
- the composition can consist essentially of a cannabinoid agent in a range of 0.005% to 1%, the cannabinoid agent including CBG; a terpene agent in a range of 0.005% to 1%; a co-fermented herbal complex in a range of 5% to 40%, wherein the co-fermented herbal complex includes ginseng , maidenhair tree ( Ginkgo biloba ), Mongolian milkvetch ( Astragalus membranaceus ), magnolia vine ( Schisandra chinensis ), fo-ti ( Polygonum multiflorum ), hardy rubber Tree ( Eucommiae ulmoides ), Solomon's seal ( Polygonatum sibirica ), hijiki seaweed (sargassum fusiforme ), white Atractylodes ( Atractylodes macrocephala ), reishi mushroom ( Ganoderma lucidum ), or any combination thereof; fermented beet crystals
- the composition can consist essentially of, on a per dose basis, a cannabinoid agent in a range of 0.5 mg to 5 mg, the cannabinoid agent including CBG; a terpene agent in a range of 1 mg to 10 mg; a co-fermented herbal complex in a range of 1500 mg to 3000 mg, wherein the co-fermented herbal complex includes ginseng , maidenhair tree ( Ginkgo biloba ), Mongolian milkvetch ( Astragalus membranaceus ), magnolia vine ( Schisandra chinensis ), fo-ti ( polygonum multiflorum ), hardy rubber Tree ( Eucommiae ulmoides ), Solomon's seal ( polygonatum sibirica ), hijiki seaweed (sargassum fusiforme ), white Atractylodes ( Atractylodes macrocephala ), reishi mushroom ( Ganoderma lucidum ), or any combination thereof; ferment
- a composition can support mental acuity through improved sleep.
- a sleep supporting composition can include a cannabinoid agent such as CBN, a terpene agent, and ashwagandha.
- the cannabinoid agent such as CBN
- the cannabinoid agent can be included in the sleep supporting composition in a range of 0.005% to 1%.
- the cannabinoid agent can be included in the sleep supporting composition in a range of 0.01% to 1%, such as a range of 0.01% to 0.5%.
- the cannabinoid agent is included in the sleep supporting composition in a range of 0.5 mg to 5 mg.
- the cannabinoid agent can be included in the sleep supporting composition in a range of 0.5 mg to 3 mg, such as a range of 1 mg to 2.5 mg.
- the terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof.
- the terpene agent can include camphene, mycene, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof.
- the terpene agent can be included in the sleep supporting composition in a range of 0.005% to 1%, such as a range of 0.005% to 1%, or a range of 0.1% to 5%.
- the terpene agent can be included in the sleep supporting composition in a range of 1 mg to 10 mg, such as a range of 2 mg to 7 mg.
- the ashwagandha can be an organic ashwagandha.
- the ashwagandha can be included in the sleep supporting composition in a range of 1% to 5%.
- the ashwagandha can be included in the sleep supporting composition in a range of 2% to 10%.
- the ashwagandha can be included in a range of 200 mg to 500 mg, such as a range of 250 mg to 400 mg.
- the sleep supporting composition can further include a co-fermented herbal complex.
- the co-fermented herbal complex can include Chinese jujube seed ( Ziziphus jujuba ), Chinese thoroughwax ( Bupleurum falcatum ), Chinese senega root (poygala tenuifolia ), albizia bark ( Albizzia julibrissin ), sphora root ( Sophora flavescens ), or any combination thereof.
- the co-fermented herbal complex can be included in the sleep supporting composition in a range of 5% to 40%.
- the co-fermented herbal complex can be included in the sleep supporting composition in a range of 10% to 30%, such as a range of 15% to 25%.
- the co-fermented herbal complex can be included in the sleep supporting composition in a range of 1500 mg to 3000 mg.
- the co-fermented herbal complex can be included in the sleep supporting composition in a range of 1500 mg to 2500 mg, such as a range of 1750 mg to 2250 mg.
- the sleep supporting composition can further include a hemp extract, such as a THC-free hemp extract.
- a hemp extract such as a THC-free hemp extract.
- the hemp extract can be included in the sleep supporting composition in a range of 0.1% to 2%, such as a range of 0.05% to 1%.
- the hemp extract can be included in the sleep supporting composition in a range of 5 mg to 35 mg.
- the hemp extract can be included in the sleep supporting composition in a range of 10 mg to 25 mg.
- the sleep supporting composition can further include L-theanine, such as a fermented L-theanine.
- L-theanine is included in the sleep supporting composition in a range of 1% to 10%, such as a range of 1% to 6%.
- the L-theanine can be included in the sleep supporting composition in a range of 1 mg to 400 mg, such as a range of 150 mg to 300 mg.
- the sleep supporting composition can further include xanthohumol.
- the xanthohumol can be included in the sleep supporting composition in a range of 0.01% to 2%, such as a range of 0.01% to 1%.
- the xanthohumol can be included in a range of 1 mg to 15 mg, such as a range of 3 mg to 9 mg.
- the sleep supporting composition can further include a magnesium source, such as a magnesium oxide or a magnesium salt.
- the magnesium salt can include magnesium chloride or an organic magnesium salt.
- the organic magnesium salt can include magnesium citrate, magnesium glycinate, magnesium ascorbate, or any combination thereof.
- the magnesium salt includes magnesium glycinate.
- the magnesium salt can be included in the sleep supporting composition in a range of 1% to 15%, such as a range of 2% to 10%. On a per dose basis, the magnesium salt can be included in the sleep supporting composition in a range of 100 mg to 700 mg, such as a range of 200 mg to 450 mg.
- the sleep supporting composition can also include valerian root.
- the valerian root can be included in the sleep supporting composition in a range of 0.01% to 2%, such as a range of 0.1% to 1%.
- the valerian root can be included in the sleep supporting composition in a range of 5 mg to 50 mg, such as a range of 15 mg to 35 mg.
- the sleep supporting composition can include melatonin.
- the melatonin can be included in the sleep supporting composition in a range of 0.005% to 0.5%, such as a range of 0.01% to 0.1%.
- the sleep supporting composition can include melatonin in a range of 0.1 mg to 10 mg, such as a range of 0.5 mg to 4 mg.
- the sleep supporting composition can be in a powder form.
- the sleep supporting composition can be in the form of pressed tablets or in the form of capsules.
- the sleep supporting composition can be mixed with water to form an aqueous solution.
- the sleep supporting composition can include the cannabinoid agent such as CDN, a terpene agent, ashwagandha, melatonin, and a co-fermented herbal complex.
- the terpene agent can be an agent as described above in relation to the sleep supporting composition.
- the co-fermented herbal complex can be the co-fermented herbal complex described above in relation to the sleep supporting composition.
- the sleep supporting composition may include the cannabinoid agent, the terpene agent, ashwagandha, melatonin, and the co-fermented herbal complex in the amounts and ranges described above in relation to the sleep supporting composition.
- the sleep supporting composition consists essentially of a cannabinoid agent in a range of 0.005% to 1%, the cannabinoid agent including CBN; a terpene agent in a range of 0.005% to 1%; ashwagandha in a range of 1% to 15%; hemp extract in a range of 0.01% to 2%; L-theanine in a range of 1% to 10%; xanthohumol in a range of 0.01% to 2%; magnesium salt in a range of 1% to 15%; valerian root in a range of 0.01% to 2%; melatonin in a range of 0.005% to 0.5%; and a co-fermented herbal complex in a range of 5% to 40%.
- a cannabinoid agent including CBN
- a terpene agent in a range of 0.005% to 1%
- ashwagandha in a range of 1% to 15%
- hemp extract in a range of 0.01% to 2%
- the sleep supporting composition consists essentially of, on a per dose basis, a cannabinoid agent in a range of 0.5 mg to 5 mg, the cannabinoid agent including CBN; a terpene agent in a range of 1 mg to 10 mg; ashwagandha in a range of 200 mg to 500 mg; hemp extract in a range of 5 mg to 35 mg; L-theanine in a range of 100 mg to 400 mg; xanthohumol in a range of 1 mg to 15 mg; magnesium salt in a range of 100 mg to 700 mg; valerian root in a range of 5 mg to 50 mg; melatonin in a range of 0.1 mg to 10 mg; and a co-fermented herbal complex in a range of 1500 mg to 3000 mg.
- a cannabinoid agent in a range of 0.5 mg to 5 mg, the cannabinoid agent including CBN; a terpene agent in a range of 1 mg to 10 mg; ashwagandha in
- compositions can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar, sugar alcohols, or stevia ; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof.
- the compositions can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof.
- the filler includes maltodextrin.
- the compositions can include a dispersant, such as lecithin.
- compositions including the alert composition, the sleep composition, the awake composition, and the sleep supporting composition, can be ingested.
- the composition can be mixed into water to form an aqueous solution, as illustrated at block 102 .
- the composition can be in a dry powder form having flavor, fillers, and dispersants as part of the composition.
- a scoop such as approximately 10 g, can be mixed into a water to form an aqueous solution.
- the aqueous solution can then be ingested, as illustrated at block 104 .
- a user may drink the aqueous solution.
- compositions can be in pill form, such as capsules or pressed tablets.
- pills can be ingested, for example, by swallowing.
- the compositions can be formed by mixing powdered dry ingredients.
- dry powdered ingredients can be mixed to form a dry powder composition, as illustrated at block 202 .
- the dry powdered ingredients can be mixed in quantities consistent with per dose amounts. For example, to make a 100-dose batch, dry powdered ingredients can be added at weights equal to 100 times the per dose amount.
- compositions (the alert composition, the sleep composition, the awake composition, and the sleep supporting composition) have desirable benefits when taken separately and act synergistically when used together.
- benefits inure from taking the awake composition without taking the sleep supporting composition and benefits inure from taking the sleep composition without taking the awake composition.
- additional synergistic benefits are experienced when taking both, one while awake and one near bedtime.
- users taking the alert or awake composition report greater mental acuity during waking hours.
- users report feeling less stress and better mental acuity after taking the sleep supporting composition prior to sleeping.
- users report a synergistic effect of feeling greater mental acuity and lower stress when taking both the alert or awake composition during waking hours and the sleep or sleep supporting composition prior to sleeping.
- the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion.
- a process, method, article, or apparatus that comprises a list of features is not necessarily limited only to those features but may include other features not expressly listed or inherent to such process, method, article, or apparatus.
- “or” refers to an inclusive-or and not to an exclusive-or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition includes ashwagandha in a range of 5% to 20%; plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%; coffee fruit extract in a range of 0.5% to 10%; grape seed extract in a range of 1% to 10%; Cordyceps in a range of 5% to 20%; extended-release caffeine in a range of 0.5% to 10%; whole coffee fruit extract in a range of 1% to 10%; Schisandra extract in a range of 1% to 10%; L-theanine in a range of 1% to 10%; and beet juice in a range of 20% to 60%.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/199,903, filed Mar. 12, 2021, which claims benefit of U.S. Provisional Application No. 62/988,910, filed Mar. 12, 2020, each of which is incorporated herein by reference in its entirety.
- This disclosure, in general, is directed to ingestible compositions in support of health and mental acuity and associated methods.
- Increasingly, people are reporting feeling tired, stressed, and generally in poor health. Modern stressors from the American diet to constant interaction with electronic devices to reduced sleep quality contributed to an increasing occurrence of various chronic ailments and a general feeling of malaise. In particular, operating in high stress environments with constant bombardment with information has contributed the occurrence of ailments associated with adrenal overload.
- Further, such conditions reduce sleep quality and busy lifestyles have reduced the amount of sleep many receive each night. Sleep is a time when purportedly, the brain clears waste and undergoes growth. In addition, other parts of the body, such as muscles and various organs, undergo waste removal, growth, and repairs during sleep. With both the reduced time sleeping and the poor quality of sleep, people are reporting lower productivity and less enjoyment of life. Thus, work suffers, relationships suffer, and chronic ailments arise in the absence of consistent sleep.
- As such, the stressors felt during periods of activity and the lack of quality sleep, purportedly, contributed to health issues and a general decrease in mental acuity. As such, compositions that address or improve the quality of sleep or compositions that support productivity without introducing additional stress would be desirable.
- The present disclosure may be better understood, and its numerous features and advantages made apparent to those skilled in the art by referencing the accompanying drawings.
-
FIG. 1 includes a block flow diagram of an example method of using a composition. -
FIG. 2 includes a block flow diagram of an example method of making a composition. - The use of the same reference symbols in different drawings indicates similar or identical items.
- In an embodiment, a composition includes ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, and amla in a range of 0.5% to 10%. The composition can further include one or more cannabinoid agents, such as cannabidiol (CBD), cannabinol (CBN) or cannabigerol (CBG). The composition provides benefits in both formulas for improved mental acuity, referred to herein as an alert formula or composition, and formulas for improved sleep, referred to herein as a sleep formula or composition.
- In another embodiment, the composition includes a cannabinoid agent, such as cannabinol (CBN) or cannabigerol (CBG). In an example, the composition further includes a co-fermented herbal complex in which a set of herbs are fermented together in the same solution. Optionally, the composition includes a variety of terpenes. In another example, the composition includes ashwagandha. The composition may be in the form of a powder. For example, the power can be mixed with water to form an aqueous solution that is imbibed by a user. Such compositions have use to improve both awake time mental acuity and quality of sleep.
- As used herein, percentages are expressed as a weight percent, and weights are expressed on a per dose basis. For example, if a recommended dose of the dry powder composition is 10 grams, the weights of the ingredients of the composition are expressed as weights of the ingredient within 10 grams of the dry powder composition. The compositions can be mixed with water or other liquids and the weights or weight percentages are expressed to not include the water or other liquid because more or less liquid can be used to concentrate or dilute a liquid version of the composition or formula, if any.
- The expression per-dose refers to the recommended dose provided with a product including the composition or formula and includes any dose option within the full range of dose options provided with the product. For example, if the product recommends one to two scoops as a dose, the per-dose composition includes the composition of one scoop or the composition of two scoops.
- In an example, a composition includes ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, and amla in a range of 0.5% to 10%. The composition provides benefits in both formulas for improved mental acuity, referred to herein as an alert formula or composition, and formulas for improved sleep, referred to herein as a sleep formula or composition.
- In a particular example, the composition can include the ashwagandha in a range of 7% to 15%. For example, the composition can include the ashwagandha in a range of 9% to 13%. The ashwagandha can include withanolides. For example, the composition can include withanolides in a per dose basis in a range of 5 mg to 30 mg, such as 10 mg to 20 mg.
- In another example, the composition can include the bacopa monnieri in a range of 4% to 10%. For example, the bacopa monnieri in a range of 4% to 7%. In an example, the bacopa monnieri includes bacopasides. In particular, the bacopasides can be included in a per dose basis in a range of 50 mg to 300 mg, such as 100 mg to 200 mg.
- In an additional example, the composition can include the amla (embllica officinals) in a range of 1.5% to 5%. The amla can include beta-glucogallin. For example, the composition can include the beta-glucogallin on a per dose bases in a range of 1 mg to 30 mg, such as a range of 3 mg to 10 mg.
- In a further example, the composition can include a cannabinoid agent. For example, the composition can include cannabidiol (CBD) in a range of 1% to 10%. In an example, the cannabidiol can be included in a range of 3% to 7%. In another example, the composition includes cannabinol (CBN) in a range of 0.1% to 4%. For example, the cannabinol can be present in a range of 1% to 3%.
- The composition finds particular use in either a formula or composition that enhances mental acuity (referred to herein as an alert formula or composition) or a formula or composition that improves sleep (referred to herein as a sleep formula or composition).
- In an additional example, an alert composition includes plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%. For example, the composition includes the plant-based nitric oxide-inducing ingredients are present in a range of 0.5% to 5%, such as in a range of 0.5% to 3%. In a particular example, the plant-based nitric oxide inducing ingredients can include one or more of green coffee bean extract, green tea extract, tart cherry, blueberry, broccoli, kale, or turmeric extract. For example, the pant-based nitric oxide inducing ingredients is S7™ of FutureCeuticals.
- In another example, the alert composition includes coffee fruit extract in a range of 0.5% to 10%. For example, the coffee fruit extract is present in a range of 0.5% to 5%. In another example, the coffee fruit extract is present in a range of 0.5% to 3%.
- In a further example, the alert composition includes grape seed extract in a range of 1% to 10%. For example, the grape seed extract is present in a range of 1% to 5%. In particular, the grape seed extract can include proanthocyanidins. For example, the alert composition can include 25 mg to 200 mg of the proanthocyanidins, such as 50 mg to 120 mg of the proanthocyanidins.
- In an additional example, the alert composition includes Cordyceps (Cordyceps sinensis) in a range of 5% to 20%. For example, the alert composition can include the Cordyceps in a range of 7% to 15%, such as a range of 9% to 13%. The Cordyceps can include cordycepic acid. The alert composition can include the cordycepic acid in an amount in a range of 5 mg to 50 mg, such as a range of 10 mg to 30 mg.
- In another example, the alert composition includes extended-release caffeine in a range of 0.5% to 10%. For example, the extended-release caffeine can be included in a range of 0.5% to 5%, such as a range of 0.5% to 3%. In particular, the various coffee products and extracts and the extended-release caffeine provide caffeine to the alert composition. For example, the alert composition can include 50 mg to 500 mg caffeine, such as 50 mg to 350 mg, or 100 mg to 250 mg caffeine on a per dose basis, in both or either quick release or extended-release variations.
- In a further example, the alert composition includes whole coffee fruit extract in a range of 1% to 10%. For example, the whole coffee fruit extract is present in a range of 1% to 5%.
- In an additional example, the alert composition includes Schisandra extract in a range of 1% to 10%. For example, the Schisandra extract is present in a range of 4% to 10%, such as in a range of 4% to 7%.
- In another example, the alert composition includes L-theanine in a range of 1% to 10%. For example, the L-theanine is present in a range of 4% to 10%, such as in a range of 4% to 7%.
- In an additional example, the alert composition includes beet juice in dried form in a range of 20% to 60%. For example, the beet juice is present in a range of 30% to 50%.
- The alert composition can further include dextrin and various flavorings.
- In an example, the composition can be used along with other ingredients to form a sleep composition. For the example, the sleep composition can include melatonin in a range of 0.005% to 1%. The melatonin can be included in a range of 0.01% to 0.5%, such as in a range of 0.01% to 0.1%.
- In another example, the sleep composition can include Bluenesse (Melissa officinalis leaf extract) in a range of 3% to 20%. For example, the Melissa officinalis leaf extract is present in a range of 5% to 18%, such as in a range of 10% to 15%.
- In a further example, the sleep composition can include holy basil (ocimum tenuiflorum) in a range of 20% to 60%. For example, the holy basil is present in a range of 30% to 50%.
- In another example, the sleep composition can include gamma aminobutyric acid in a range of 0.5% to 10%. For example, the gamma aminobutyric acid is present in a range of 1.5% to 5%.
- In another example, the sleep composition includes L-theanine in a range of 1% to 10%. For example, the L-theanine is present in a range of 4% to 10%, such as in a range of 6% to 9%.
- In a particular example, an alert composition consists essentially of ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, amla in a range of 0.5% to 10%, cannabidiol in a range of 1% to 10%, cannabinol in a range of 0.1% to 4%, plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%, coffee fruit extract in a range of 0.5% to 10%, grape seed extract in a range of 1% to 10%, Cordyceps in a range of 5% to 20%, extended-release caffeine in a range of 0.5% to 10%, whole coffee fruit extract in a range of 1% to 10%, Schisandra extract in a range of 1% to 10%, L-theanine in a range of 1% to 10%, beet juice in a range of 20% to 60%, and dextrin.
- In an example, the plant-based nitric oxide inducing ingredients include one or more of green coffee bean extract, green tea extract, tart cherry, blueberry, broccoli, kale, or turmeric extract.
- In a particular example, a sleep composition consists essentially of ashwagandha in a range of 5% to 20%, bacopa monnieri in a range of 1% to 10%, amla in a range of 0.5% to 10%, cannabidiol in a range of 1% to 10%, cannabinol in a range of 0.1% to 4%, melatonin in a range of 0.005% to 1%, Melissa officinalis leaf extract in a range of 3% to 20%, holy basil (ocimum tenuiflorum) in a range of 20% to 60%, and gamma aminobutyric acid in a range of 0.5% to 10%. The sleep composition can further include sweeteners and flavorings.
- In a further example, an alternative alert composition consists essentially of complex terpenes in a range of 0.5% to 10%, coffee fruit extract in a range of 5% to 20%, organic coffeeberry in a range of 5% to 20%, plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%, cannabidiol in a range of 0.1% to 5%, cannabinol in a range of 0.1% to 3%, epigallocatechin gallate in a range of 0.005% to 1%, and resveratrol in a range of 0.005% to 1%. The composition can further include sweeteners, such as dextrin and monk fruit extract, and flavorings, such as citric acid.
- In an example, the complex terpenes are present in a range of 0.5% to 5%, such as in a range of 0.5% to 3%. For example, the complex terpenes can include alpha pinene, limonene, beta caryophyllene, phytol, alpha phellandrene, alpha-humulene, nerolidol, myrcene, linalool, terpinolene, or any combination thereof.
- In another example, the coffee fruit extract is present in a range of 10% to 15%. In a further example, the organic coffeeberry is present in a range of 10% to 15%.
- In an additional example, the plant-based nitric oxide-inducing ingredients in a range of 1% to 10%, such as in a range of 2% to 8%.
- In a further example, the cannabidiol is present in a range of 0.5% to 3%. In an additional example, the cannabinol is present in a range of 0.5% to 2%.
- In another example, the epigallocatechin gallate is present in a range of 0.01% to 0.5%. For example, the epigallocatechin gallate is present in a range of 0.01% to 0.1%.
- In a further example, the resveratrol is present in a range of 0.01% to 0.5%. For example, the resveratrol is present in a range of 0.01% to 0.1%.
- In another alternative example, the composition includes a cannabinoid agent, a terpene agent, and co-fermented herbal complex. For example, the composition may be a dry powdered mixture. In another example, the composition can be in the form of an aqueous solution.
- The cannabinoid agent can include CBD (cannabidiol), CBDA (cannabidiolic acid), CBN (cannabinol), CBG (cannabigerol), CBC (cannabichromene), CBL (cannabicyclol), CBV (cannabivarin), THCV (tetrahydrocannabivarin), CBDV (cannabidivarin), CBCV (cannabichromevarin), CBGV (cannabigerovarin), CBGM (cannabigerol monomethyl ether), CBE (cannabielsoin), CBT (cannabicitran), or any combination thereof. In general, the cannabinoid agent is free of THC (tetrahydrocannabinol) or THCA (tetrahydrocannabinolic acid). In particular, the cannabinoid includes CBD, CBN, CBG, or combination thereof. In example, the cannabinoid agent includes CBG. In another example, the cannabinoid agent includes CBN. The cannabinoid agent can be included in the composition in a range of 0.005% to 1%. For example, the cannabinoid agent can be included in the composition in a range of 0.01% to 1%, such as a range of 0.01% to 0.5%.
- The terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof. In an example, the terpene agent includes a mixture including limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, or a combination thereof. In another example, the terpene agent includes camphene, mycene, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof. The terpene agent can be included in the composition in a range of 0.005% to 1%. For example, the terpene agent can be included in the composition in a range of 0.1% to 0.5%.
- Regarding the co-fermented herbal complex, each of the ingredients can be fermented together and subsequently dried to form a powder complex having synergistic properties. In an example, the co-fermented herbal complex can include ginseng, maidenhair tree (Ginkgo biloba), Mongolian milkvetch (Astragalus membranaceus), magnolia vine (Schisandra chinensis), fo-ti (polygonum multiflorum), hardy rubber Tree (Eucommiae ulmoides), Solomon's seal (polygonatum sibirica), hijiki seaweed (sargassum fusiforme), white atractylodes (Atractylodes macrocephala), reishi mushroom (Ganoderma lucidum), or any combination thereof. The ginseng of the co-fermented herbal complex can include Siberian ginseng (eletherococcus senticosus), Chinese ginseng (panax ginseng), southern ginseng (Gynostemma pentaphylla), or any combination thereof. The co-fermented herbal complex can further include jujube fruit (Ziziphus jujuba), Goji berry (lycium barbarum), monk fruit (momordica grosvenori), or any combination thereof. In another example, the for co-fermented herbal complex includes Siberian ginseng (eletherococcus senticosus), maidenhair tree (Ginkgo biloba), Mongolian milkvetch (Astragalus membranaceus), Chinese ginseng (panax ginseng), magnolia vine (Schisandra chinensis), fo-ti (Polygonum multiflorum), hardy rubber Tree (Eucommiae ulmoides), Solomon's seal (polygonatum sibirica), southern ginseng (Gynostemma pentaphylla), hijiki seaweed (sargassum fusiforme), white atractylodes (Atractylodes macrocephala), reishi mushroom (Ganoderma lucidum), jujube fruit (Ziziphus jujuba), Goji berry (Lycium barbarum), monk fruit (momordica grosvenori), or any combination thereof. In a further example, the co-fermented herbal complex includes Chinese jujube seed (Ziziphus jujuba), Chinese thoroughwax (Bupleurum falcatum), Chinese senega root (poygala tenuifolia), albizia bark (Albizzia julibrissin), sphora root (Sophora flavescens), or any combination thereof.
- The co-fermented herbal complex can be included in the composition in a range of 5% to 40%. For example, the co-fermented herbal complex is included in the composition in a range of 10% to 30%, such as a range of 15% to 35%.
- The composition can further include fermented beet. For example, the fermented beet can be fermented beet crystals. The fermented beet can be included in the composition in the range of 1% to 30%, such as a range of 5% to 20%.
- In addition, the composition can include Rhodiola rosea. The Rhodiola rosea can be a fermented Rhodiola rosea. In an example, the Rhodiola rosea is included in the composition in a range of 1% to 10%, such as a range of 2% to 7%.
- The composition can further include Cordyceps sinensis. The Cordyceps sinensis can include fermented Cordyceps sinensis. In the example, the Cordyceps sinensis is included in the composition in a range of 1% to 10%, such as a range of 2% to 7%.
- In a further example, the composition can include hemp extract, such as THC-free hemp extract. The hemp extract can be included in the composition in a range of 0.01% to 2%, such as a range of 0.05% to 1%.
- In an additional example, the composition can include bacopa monnieri. The bacopa monnieri can be included in the composition in a range of 1% to 10%. For example, the bacopa monnieri can be included in a range of 2% to 7%.
- The composition can also include L-theanine, such as fermented L-theanine. In an example, the L-theanine is included in the composition in a range of 1% to 10%, such as a range of 1% to 6%.
- In another example, the composition can include whole bean coffee fruit powder. For example, the whole bean coffee fruit powder can be included in the composition in a range of 0.1% to 5%. For example, the whole bean coffee fruit powder can be included in the composition in a range of 0.5% to 3%.
- The composition can also include caffeine, such as an organic derived caffeine. The caffeine can be included in the composition in a range of 0.5% to 10%, such as a range of 1% to 5%.
- The composition can also include a nitric oxide booster. In an example, the nitric oxide booster includes coffee bean extract, green tea extract, turmeric extract, tart cherry, blueberry, broccoli, kale, or any combination thereof. The nitric oxide booster can be included in the composition in a range of 0.01% to 5%, such as a range of 0.1% to 2%.
- In another example, the composition can include astaxanthin. For example, the composition can include astaxanthin in a range of 0.01% to 2%, such as a range of 0.01% to 1%.
- In an additional example, the composition can include xanthohumol. For example, the composition can include the xanthohumol in a range of 0.01% to 2%, such as a range of 0.01% to 1%.
- In a further example, the composition can include a source of magnesium, such as magnesium oxide or magnesium salt. The magnesium salt can include magnesium chloride, magnesium nitrate, or an organic magnesium salt. In particular, the magnesium salt can be an organic magnesium salt, such as magnesium citrate, magnesium glycinate, magnesium ascorbate, or any combination thereof. The magnesium salt can be included in the composition in the range of 1% to 15%, such as a range of 2% to 10%.
- In another example, the composition can include ashwagandha, such as an organic ashwagandha. For example, the ashwagandha can be included in the composition in a range of 1% to 15%, such as a range of 2% to 10%.
- In a further example, the composition can include valerian root. For example, the valerian root can be included in the composition in a range of 0.1% to 2%, such as a range of 0.1% to 1%.
- In a further example, the composition can include melatonin. The melatonin can be included in a composition in a range of 0.005% to 0.5%, such as a range of 0.01% to 0.1%.
- The composition can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar or stevia; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof. The composition can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof. In a particular example, the filler includes maltodextrin. In a further example, the composition can include a dispersant, such as lecithin.
- The composition can be in a powder form. Alternatively, the composition can be in the form of pressed tablets or in the form of capsules. In a further example, the composition can be mixed with water to form an aqueous solution.
- In a particular example, an awake composition can promote mental acuity during periods when users are awake. For example, the composition can include a cannabinoid agent, such as CBG, a terpene agent, and a co-fermented herbal complex. Optionally, the awake composition can include Rhodiola rosea, Cordyceps sinensis, or astaxanthin, or any combination thereof.
- In an example, the awake composition includes the cannabinoid agent in a range of 0.05% to 1%. For example, the cannabinoid agent can be included in the awake composition in a range of 0.01% to 1%, such as a range of 0.1% to 0.5%. On a per dose basis, the cannabinoid agent can be included in the awake composition in a range of 0.5 mg to 5 mg. For example, the cannabinoid agent can be included in the awake composition in a range of 0.5 mg to 3 mg, such as a range of 1 mg to 2.5 mg.
- The terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof. For example, the terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, or a combination thereof. In an example, the terpene agent is included in the awake composition in a range of 0.05% to 1%. For example, the terpene agent can be included in the awake composition in a range of 0.005% to 1%, such as a range of 0.1% to 0.5%. On a per dose basis, the terpene agent can be included in the awake composition in a range of 1 mg to 10 mg. For example, the terpene agent can be included in the awake composition in a range of 2 mg to 7 mg.
- The co-fermented herbal complex can include ginseng, maidenhair tree (Ginkgo biloba), Mongolian milkvetch (Astragalus membranaceus), magnolia vine (Schisandra chinensis), fo-ti (Polygonum multiflorum), hardy rubber Tree (eucommiae ulmoides), Solomon's seal (polygonatum sibirica), hijiki seaweed (sargassum fusiforme), white Atractylodes (Atractylodes macrocephala), reishi mushroom (Ganoderma lucidum), or any combination thereof. The ginseng of the co-fermented herbal complex can include Siberian ginseng (eletherococcus senticosus), Chinese ginseng (panax ginseng), southern ginseng (Gynostemma pentaphylla), or any combination thereof. The co-fermented herbal complex can further include jujube fruit (Ziziphus jujuba), Goji berry (Lycium barbarum), monk fruit (Momordica grosvenori), or any combination thereof.
- The co-fermented herbal complex can be included in the awake composition in a range of 5% to 40%. For example, the co-fermented herbal complex can be included in the awake composition in a range of 10% to 30%, such as a range of 15% to 25%. On a per dose basis, the co-fermented herbal complex can be included in the awake composition in a range of 1500 mg to 3000 mg. For example, the co-fermented herbal complex can be included in the awake composition in a range of 1500 mg to 2500 mg, such as a range of 1750 mg to 2250 mg.
- The Rhodiola rosea can be a fermented Rhodiola rosea. In an example, the Rhodiola rosea can be included in the awake composition in a range of 1% to 10%. For example, the Rhodiola rosea can be included in the awake composition in a range of 2% to 7%. On a per dose basis, the Rhodiola rosea can be included in the awake composition in a range of 200 mg to 500 mg. For example, the Rhodiola rosea can be included in the awake composition in a range of 300 mg to 400 mg.
- The Cordyceps sinensis can be fermented Cordyceps sinensis. In an example, the Cordyceps sinensis can be included in the awake composition in a range of 1% to 10%. For example, the Cordyceps sinensis can be included in the awake composition in a range of 2% to 7%. On a per dose basis, the Cordyceps sinensis can be included in the awake composition in a range of 200 mg to 500 mg. For example, the Cordyceps sinensis can be included in the awake composition in a range of 300 mg to 400 mg.
- The astaxanthin can be included in the awake composition in a range of 0.01% to 2%. For example, the astaxanthin can be included in the awake composition in a range of 0.01% to 1%. On a per dose basis, the astaxanthin can be included in the awake composition in a range of 1 mg to 20 mg, such as a range of 2 mg to 15 mg.
- The composition can further include fermented beet, such as fermented beet crystals. In an example, the fermented beet can be included in the awake composition in a range of 1% to 30%, such as a range of 5% to 20%. On a per dose basis, the fermented beet can be included in the awake composition in a range of 600 mg to 1800 mg. For example, the fermented beet can be included in the awake composition in a range of 1000 mg to 1400 mg.
- The composition can further include hemp extract, such as THC-free hemp extract. In an example, the hemp extract is included in the awake composition in a range of 0.01% to 2%, such as a range of 0.05% to 1%. On a per dose basis, the hemp extract can be included in the awake composition in a range of 5 mg to 35 mg, such as a range of 10 mg to 25 mg.
- The awake composition can further include bacopa monnieri. The bacopa monnieri can be included in the awake composition in a range of 1% to 10%, such as a range of 2% to 7%. On a per dose basis, the bacopa monnieri can be included in the awake composition in a range of 150 mg to 500 mg. For example, the bacopa monnieri can be included in the awake composition in a range of 200 mg to 400 mg.
- The awake composition can also include L-theanine, such as a fermented L-theanine. In an example, the L-theanine is included in the awake composition in a range of 1% to 10%, such as a range of 1% to 6%. On a per dose basis, the L-theanine can be included in the awake composition in a range of 100 mg to 400 mg, such as a range of 150 mg to 300 mg.
- The awake composition can also include whole coffee being fruit powder. For example, the whole coffee bean fruit powder can be included in the awake composition in a range of 0.1% to 5%, such as a range of 0.5% to 3%. On a per dose basis, the whole coffee bean fruit powder can be included in the awake composition in a range of 10 mg to 300 mg, such as a range of 50 mg to 250 mg.
- The awake composition can also include caffeine. For example, the caffeine can be included in the awake composition in a range of 0.5% to 10%, such as a range of 1% to 5%. On a per dose basis, the caffeine is included in the awake composition in a range of 20 mg to 500 mg, such as a range of 100 mg to 400 mg.
- The awake composition can further include a nitric oxide booster. In an example, the nitric oxide booster includes coffee bean extract, green tea extract, turmeric extract, tart cherry, blueberry, broccoli, kale, or any combination thereof. The nitric oxide booster can be included in the awake composition in a range of 0.1% to 5%, such as a range of 0.1% to 2%. On a per dose basis, the nitric oxide booster can be included in the awake composition in a range of 10 mg to 150 mg. For example, the nitric oxide booster can be included in the awake composition in a range of 25 mg to 90 mg.
- The awake composition can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar, sugar alcohols, or stevia; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof. The composition can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof. In a further example, the composition can include a dispersant, such as lecithin.
- The awake composition can be in a powder form. Alternatively, the awake composition can be in the form of pressed tablets or in the form of capsules. In a further example, the awake composition can be mixed with water to form an aqueous solution.
- In a particular example, the composition can consist essentially of a cannabinoid agent in a range of 0.005% to 1%, the cannabinoid agent including CBG; a terpene agent in a range of 0.005% to 1%; a co-fermented herbal complex in a range of 5% to 40%, wherein the co-fermented herbal complex includes ginseng, maidenhair tree (Ginkgo biloba), Mongolian milkvetch (Astragalus membranaceus), magnolia vine (Schisandra chinensis), fo-ti (Polygonum multiflorum), hardy rubber Tree (Eucommiae ulmoides), Solomon's seal (Polygonatum sibirica), hijiki seaweed (sargassum fusiforme), white Atractylodes (Atractylodes macrocephala), reishi mushroom (Ganoderma lucidum), or any combination thereof; fermented beet crystals in a range of 1% to 30%; fermented Rhodiola rosea in a range of 1% to 10%; fermented Cordyceps sinensis in a range of 1% to 10%; hemp extract in a range of 0.01% to 2%; bacopa monnieri in a range of 1% to 10%; L-theanine in a range of 1% to 10%; whole bean coffee fruit powder in a range of 0.1% to 5%; nitric oxide booster in a range of 0.01% to 5%; caffeine in a range of 0.5% to 10%; and astaxanthin in a range of 0.01% to 2%.
- In another example, the composition can consist essentially of, on a per dose basis, a cannabinoid agent in a range of 0.5 mg to 5 mg, the cannabinoid agent including CBG; a terpene agent in a range of 1 mg to 10 mg; a co-fermented herbal complex in a range of 1500 mg to 3000 mg, wherein the co-fermented herbal complex includes ginseng, maidenhair tree (Ginkgo biloba), Mongolian milkvetch (Astragalus membranaceus), magnolia vine (Schisandra chinensis), fo-ti (polygonum multiflorum), hardy rubber Tree (Eucommiae ulmoides), Solomon's seal (polygonatum sibirica), hijiki seaweed (sargassum fusiforme), white Atractylodes (Atractylodes macrocephala), reishi mushroom (Ganoderma lucidum), or any combination thereof; fermented beet crystals in a range of 600 mg to 1800 mg; fermented Rhodiola rosea in a range of 200 mg to 500 mg; fermented Cordyceps sinensis in a range of 200 mg to 500 mg; hemp extract in a range of 5 mg to 35 mg; bacopa monnieri in a range of 150 mg to 500 mg; L-theanine in a range of 100 mg to 400 mg; whole bean coffee fruit powder in a range of 10 mg to 300 mg; nitric oxide booster in a range of 10 mg to 150 mg; caffeine in a range of 20 mg to 500 mg; and astaxanthin in a range of 1 mg to 20 mg.
- In another example, a composition can support mental acuity through improved sleep. In an example, a sleep supporting composition can include a cannabinoid agent such as CBN, a terpene agent, and ashwagandha.
- In an example, the cannabinoid agent, such as CBN, can be included in the sleep supporting composition in a range of 0.005% to 1%. For example, the cannabinoid agent can be included in the sleep supporting composition in a range of 0.01% to 1%, such as a range of 0.01% to 0.5%. On a per dose basis, the cannabinoid agent is included in the sleep supporting composition in a range of 0.5 mg to 5 mg. For example, the cannabinoid agent can be included in the sleep supporting composition in a range of 0.5 mg to 3 mg, such as a range of 1 mg to 2.5 mg.
- The terpene agent can include limonene, alpha pinene, beta pinene, camphene, mycene, eucalyptol, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof. For example, the terpene agent can include camphene, mycene, terpinolene, alpha bislol, beta caryophyllene, humulene, linalool, nerolidol, ocimene, or a combination thereof. In an example, the terpene agent can be included in the sleep supporting composition in a range of 0.005% to 1%, such as a range of 0.005% to 1%, or a range of 0.1% to 5%. On a per dose basis, the terpene agent can be included in the sleep supporting composition in a range of 1 mg to 10 mg, such as a range of 2 mg to 7 mg.
- The ashwagandha can be an organic ashwagandha. The ashwagandha can be included in the sleep supporting composition in a range of 1% to 5%. For example, the ashwagandha can be included in the sleep supporting composition in a range of 2% to 10%. On a per dose basis, the ashwagandha can be included in a range of 200 mg to 500 mg, such as a range of 250 mg to 400 mg.
- The sleep supporting composition can further include a co-fermented herbal complex. For example, the co-fermented herbal complex can include Chinese jujube seed (Ziziphus jujuba), Chinese thoroughwax (Bupleurum falcatum), Chinese senega root (poygala tenuifolia), albizia bark (Albizzia julibrissin), sphora root (Sophora flavescens), or any combination thereof. The co-fermented herbal complex can be included in the sleep supporting composition in a range of 5% to 40%. For example, the co-fermented herbal complex can be included in the sleep supporting composition in a range of 10% to 30%, such as a range of 15% to 25%. On a per dose basis, the co-fermented herbal complex can be included in the sleep supporting composition in a range of 1500 mg to 3000 mg. For example, the co-fermented herbal complex can be included in the sleep supporting composition in a range of 1500 mg to 2500 mg, such as a range of 1750 mg to 2250 mg.
- The sleep supporting composition can further include a hemp extract, such as a THC-free hemp extract. For example, the hemp extract can be included in the sleep supporting composition in a range of 0.1% to 2%, such as a range of 0.05% to 1%. On a per dose basis, the hemp extract can be included in the sleep supporting composition in a range of 5 mg to 35 mg. For example, the hemp extract can be included in the sleep supporting composition in a range of 10 mg to 25 mg.
- The sleep supporting composition can further include L-theanine, such as a fermented L-theanine. In an example, the L-theanine is included in the sleep supporting composition in a range of 1% to 10%, such as a range of 1% to 6%. On a per dose basis, the L-theanine can be included in the sleep supporting composition in a range of 1 mg to 400 mg, such as a range of 150 mg to 300 mg.
- The sleep supporting composition can further include xanthohumol. For example, the xanthohumol can be included in the sleep supporting composition in a range of 0.01% to 2%, such as a range of 0.01% to 1%. On a per dose basis, the xanthohumol can be included in a range of 1 mg to 15 mg, such as a range of 3 mg to 9 mg.
- The sleep supporting composition can further include a magnesium source, such as a magnesium oxide or a magnesium salt. In an example, the magnesium salt can include magnesium chloride or an organic magnesium salt. For example, the organic magnesium salt can include magnesium citrate, magnesium glycinate, magnesium ascorbate, or any combination thereof. In a particular example, the magnesium salt includes magnesium glycinate. The magnesium salt can be included in the sleep supporting composition in a range of 1% to 15%, such as a range of 2% to 10%. On a per dose basis, the magnesium salt can be included in the sleep supporting composition in a range of 100 mg to 700 mg, such as a range of 200 mg to 450 mg.
- The sleep supporting composition can also include valerian root. For example, the valerian root can be included in the sleep supporting composition in a range of 0.01% to 2%, such as a range of 0.1% to 1%. On a per dose basis, the valerian root can be included in the sleep supporting composition in a range of 5 mg to 50 mg, such as a range of 15 mg to 35 mg.
- In addition, the sleep supporting composition can include melatonin. For example, the melatonin can be included in the sleep supporting composition in a range of 0.005% to 0.5%, such as a range of 0.01% to 0.1%. On a per dose basis, the sleep supporting composition can include melatonin in a range of 0.1 mg to 10 mg, such as a range of 0.5 mg to 4 mg.
- The sleep supporting composition can be in a powder form. Alternatively, the sleep supporting composition can be in the form of pressed tablets or in the form of capsules. In a further example, the sleep supporting composition can be mixed with water to form an aqueous solution.
- In a further example, the sleep supporting composition can include the cannabinoid agent such as CDN, a terpene agent, ashwagandha, melatonin, and a co-fermented herbal complex. For example, the terpene agent can be an agent as described above in relation to the sleep supporting composition. The co-fermented herbal complex can be the co-fermented herbal complex described above in relation to the sleep supporting composition. The sleep supporting composition may include the cannabinoid agent, the terpene agent, ashwagandha, melatonin, and the co-fermented herbal complex in the amounts and ranges described above in relation to the sleep supporting composition.
- In a particular example, the sleep supporting composition consists essentially of a cannabinoid agent in a range of 0.005% to 1%, the cannabinoid agent including CBN; a terpene agent in a range of 0.005% to 1%; ashwagandha in a range of 1% to 15%; hemp extract in a range of 0.01% to 2%; L-theanine in a range of 1% to 10%; xanthohumol in a range of 0.01% to 2%; magnesium salt in a range of 1% to 15%; valerian root in a range of 0.01% to 2%; melatonin in a range of 0.005% to 0.5%; and a co-fermented herbal complex in a range of 5% to 40%.
- In a further example, the sleep supporting composition consists essentially of, on a per dose basis, a cannabinoid agent in a range of 0.5 mg to 5 mg, the cannabinoid agent including CBN; a terpene agent in a range of 1 mg to 10 mg; ashwagandha in a range of 200 mg to 500 mg; hemp extract in a range of 5 mg to 35 mg; L-theanine in a range of 100 mg to 400 mg; xanthohumol in a range of 1 mg to 15 mg; magnesium salt in a range of 100 mg to 700 mg; valerian root in a range of 5 mg to 50 mg; melatonin in a range of 0.1 mg to 10 mg; and a co-fermented herbal complex in a range of 1500 mg to 3000 mg.
- The above compositions can further include flavoring, such as fruit flavoring or extracts; sweeteners, such as sugar, sugar alcohols, or stevia; salts, such as sodium chloride or potassium chloride; citric acid; or any combination thereof. The compositions can also include fillers, such as starch, maltodextrin, sodium carbonate, sodium bicarbonate, calcium carbonate, or any combination thereof. In a particular example, the filler includes maltodextrin. In a further example, the compositions can include a dispersant, such as lecithin.
- The above compositions, including the alert composition, the sleep composition, the awake composition, and the sleep supporting composition, can be ingested. In an
example method 100 illustrated inFIG. 1 , the composition can be mixed into water to form an aqueous solution, as illustrated atblock 102. For example, the composition can be in a dry powder form having flavor, fillers, and dispersants as part of the composition. A scoop, such as approximately 10 g, can be mixed into a water to form an aqueous solution. The aqueous solution can then be ingested, as illustrated atblock 104. For example, a user may drink the aqueous solution. - Alternatively, the compositions can be in pill form, such as capsules or pressed tablets. In such an example, the pills can be ingested, for example, by swallowing.
- The compositions, including the awake composition and the sleep supporting composition, can be formed by mixing powdered dry ingredients. For example, in a
method 200 illustrated inFIG. 2 , dry powdered ingredients can be mixed to form a dry powder composition, as illustrated atblock 202. The dry powdered ingredients can be mixed in quantities consistent with per dose amounts. For example, to make a 100-dose batch, dry powdered ingredients can be added at weights equal to 100 times the per dose amount. - Each of the compositions (the alert composition, the sleep composition, the awake composition, and the sleep supporting composition) have desirable benefits when taken separately and act synergistically when used together. In other words, benefits inure from taking the awake composition without taking the sleep supporting composition, and benefits inure from taking the sleep composition without taking the awake composition. And, additional synergistic benefits are experienced when taking both, one while awake and one near bedtime.
- In particular, users taking the alert or awake composition report greater mental acuity during waking hours. Similarly, users report feeling less stress and better mental acuity after taking the sleep supporting composition prior to sleeping. Moreover, users report a synergistic effect of feeling greater mental acuity and lower stress when taking both the alert or awake composition during waking hours and the sleep or sleep supporting composition prior to sleeping.
- Note that not all of the activities described above in the general description or the examples are required, that a portion of a specific activity may not be required, and that one or more further activities may be performed in addition to those described. Still further, the order in which activities are listed are not necessarily the order in which they are performed.
- In the foregoing specification, the concepts have been described with reference to specific embodiments. However, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification and figures are to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.
- As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having” or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, article, or apparatus that comprises a list of features is not necessarily limited only to those features but may include other features not expressly listed or inherent to such process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive-or and not to an exclusive-or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
- Also, the use of “a” or “an” are employed to describe elements and components described herein. This is done merely for convenience and to give a general sense of the scope of the invention. This description should be read to include one or at least one and the singular also includes the plural unless it is obvious that it is meant otherwise.
- Benefits, other advantages, and solutions to problems have been described above with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any feature(s) that may cause any benefit, advantage, or solution to occur or become more pronounced are not to be construed as a critical, required, or essential feature of any or all the claims.
- After reading the specification, skilled artisans will appreciate that certain features are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination. Further, references to values stated in ranges include each and every value within that range.
Claims (20)
1. A composition comprising by weight percent thereof:
ashwagandha in a range of 5% to 20%;
plant-based nitric oxide-inducing ingredients in a range of 0.5% to 10%;
coffee fruit extract in a range of 0.5% to 10%;
grape seed extract in a range of 1% to 10%;
Cordyceps in a range of 5% to 20%;
extended-release caffeine in a range of 0.5% to 10%;
whole coffee fruit extract in a range of 1% to 10%;
Schisandra extract in a range of 1% to 10%;
L-theanine in a range of 1% to 10%; and
beet juice in a range of 20% to 60%.
2. The composition of claim 1 , wherein the ashwagandha is present in a range of 7% to 15%.
3. The composition of claim 2 , wherein the ashwagandha is present in a range of 9% to 13%.
4. The composition of claim 1 , wherein the ashwagandha includes withanolides in a per dose range of 5 mg to 30 mg.
5. The composition of claim 4 , where in the per does range is 10 mg to 20 mg.
6. The composition of claim 1 , wherein the plant-based nitric oxide-inducing ingredients are present in a range of 0.5% to 5%.
7. The composition of claim 6 , wherein the plant-based nitric oxide-inducing ingredients are present in a range of 0.5% to 3%.
8. The composition of claim 1 , wherein the plant-based nitric oxide inducing ingredients include one or more of green coffee bean extract, green tea extract, tart cherry, blueberry, broccoli, kale, or turmeric extract.
9. The composition of claim 1 , wherein the coffee fruit extract is present in a range of 0.5% to 5%.
10. The composition of claim 9 , wherein the coffee fruit extract is present in a range of 0.5% to 3%.
11. The composition of claim 1 , wherein the grape seed extract is present in a range of 1% to 5%
12. The composition of claim 1 , wherein the Cordyceps is present in a range of 7% to 15%.
13. The composition of claim 12 , wherein the Cordyceps is present in a range of 9% to 13%.
14. The composition of claim 1 , wherein the extended-release caffeine is present in a range of 0.5% to 5%.
15. The composition of claim 14 , wherein the whole coffee fruit extract is present in a range of 1% to 5%.
16. The composition of claim 1 , wherein the Schisandra extract is present in a range of 4% to 10%.
17. The composition of claim 16 , wherein the Schisandra extract is present in a range of 4% to 7%.
18. The composition of claim 1 , wherein L-theanine is present in a range of 4% to 10%.
19. The composition of claim 17 , wherein L-theanine is present in a range of 4% to 7%.
20. The composition of claim 1 , wherein the beet juice is present in a range of 30% to 50%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/107,348 US20230181487A1 (en) | 2020-03-12 | 2023-02-08 | Compositions in support of health and mental accuity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062988910P | 2020-03-12 | 2020-03-12 | |
US17/199,903 US11596610B2 (en) | 2020-03-12 | 2021-03-12 | Compositions in support of health and mental accuity |
US18/107,348 US20230181487A1 (en) | 2020-03-12 | 2023-02-08 | Compositions in support of health and mental accuity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/199,903 Continuation US11596610B2 (en) | 2020-03-12 | 2021-03-12 | Compositions in support of health and mental accuity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230181487A1 true US20230181487A1 (en) | 2023-06-15 |
Family
ID=77664078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/199,903 Active 2041-04-09 US11596610B2 (en) | 2020-03-12 | 2021-03-12 | Compositions in support of health and mental accuity |
US18/107,348 Pending US20230181487A1 (en) | 2020-03-12 | 2023-02-08 | Compositions in support of health and mental accuity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/199,903 Active 2041-04-09 US11596610B2 (en) | 2020-03-12 | 2021-03-12 | Compositions in support of health and mental accuity |
Country Status (1)
Country | Link |
---|---|
US (2) | US11596610B2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10325156A1 (en) * | 2003-05-28 | 2004-12-23 | Coty B.V. | Active ingredient preparation with plant extracts for cosmetics |
WO2015054694A2 (en) * | 2013-10-13 | 2015-04-16 | 4Life Patents, Llc | Therapeutic compositions and methods for addressing physiological stresses and aging |
CN106456525B (en) * | 2014-04-17 | 2019-12-03 | 荷兰联合利华有限公司 | Aloe extract for personal care composition |
IT201600078969A1 (en) * | 2016-07-27 | 2018-01-27 | Buonamici Gugliemo | DIETARY SUPPLEMENT |
FR3080990A1 (en) * | 2018-05-09 | 2019-11-15 | Nor-Feed Sas | INCREASING THE ESSENTIAL FATTY ACID CONTENT OF EGGS THROUGH NUTRITIONAL SUPPLEMENTATION OF ANIMALS USING A VERY LOW DOSE OF A FLAVONOID-RICH PLANT EXTRACT |
-
2021
- 2021-03-12 US US17/199,903 patent/US11596610B2/en active Active
-
2023
- 2023-02-08 US US18/107,348 patent/US20230181487A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11596610B2 (en) | 2023-03-07 |
US20210283070A1 (en) | 2021-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rejhová et al. | Natural compounds and combination therapy in colorectal cancer treatment | |
US5904924A (en) | Green nutritional powder composition | |
Nag et al. | Ginsenosides as anticancer agents: in vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action | |
Stuart et al. | Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer | |
TWI666021B (en) | Composition containing oligofructose and quercetin glycoside | |
JP2003503324A (en) | Effervescent green tea extract preparation | |
CN105053325A (en) | Microcapsule peruvian ginseng tea and preparation method thereof | |
CN103610053A (en) | High-purity grape seed extract tablet and preparation method thereof | |
CN102450536A (en) | Composition for suppressing appetite, removing toxin, losing weight and eliminating fat | |
CN103156896A (en) | Preparation method for novel red ginseng using reduced-pressure drying after high temperature high pressure process | |
West et al. | A double-blind clinical safety study of noni fruit juice | |
TWI679985B (en) | Tie2 activator with olive fruit extract | |
US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
CN105147985A (en) | Preparation with effects of clearing throat and moistening lung | |
Ridker | Toxic effects of herbal teas | |
WO2018112475A1 (en) | Energy compositions and methods | |
US11596610B2 (en) | Compositions in support of health and mental accuity | |
Jaruchotikamol et al. | Cytoprotective activity of mulberry leaf extract against oxidative stress-induced cellular injury in rats. | |
Sarma et al. | Green tea: Current trends and prospects in nutraceutical and pharmaceutical aspects | |
EP3246040A1 (en) | Pomegranate extract for alleviating women's menopausal symptoms, containing high content of ellagic acid | |
CN100348261C (en) | Chinese medicine for lowering blood pressure and reducing blood fat and its prepn | |
KR20170086198A (en) | Manufacturing method of diet solid tea including fermentation herb remedy and dietary fiber and the solid tea produced thereby | |
WO2014148883A1 (en) | Herbaceutical formulations | |
CN112587635A (en) | Chinese herbal medicine for treating damaged pancreatic tissue, package and production method thereof | |
KR20180131651A (en) | Composition for anti-oxidation containing the complex extracts of white ginseng, Agrimonia pilosa, Salvia miltiorrhiza and Solidago virgaurea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |